Expert alert: San Diego scientist available to comment on local dengue case
LJI Professor Sujan Shresta, Ph.D., is a leader in dengue virus research and vaccine development
Lab Shresta
New mouse models offer valuable window into COVID-19 infection
LJI and Synbal, Inc. scientists develop new tool for pandemic preparedness
LJI Professor Sujan Shresta wins new funding to investigate dengue and chikungunya virus vaccines
Shresta and her LJI colleagues work toward pandemic preparedness as members of the national 'ReVAMPP' network
Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease
CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination
Important advances in the field of anti-dengue virus research
STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor
Better late than never: antivirals for dengue
Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design
Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a high conserved sequence
Role of complement in dengue virus infection: protection or pathogenesis?
Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice
Tracking the evolution of dengue virus strains D2S10 and D2S20 by 454 pyrosequencing
Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells
An iminosugar with potent inhibition of dengue virus infection in vivio
Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses
Role of humoral versus cellular responses induced by a protective dengue vaccine candidate
Animal models in dengue
Dengue virus vaccine development
The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus
Mouse models to study dengue virus immunology and pathogenesis
Mouse models for dengue vaccines and antivirals
Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondard infection
CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice
Dengue viral evolution under a hose-targeted antiviral
A novel iminosugar UV-12 with activity against the diverse viruses influenza and dengue (novel iminosugar antiviral for influenza and dengue)
CD8+ T cells can mediate short-term protection against heterotypic dengue reinfection in mice
Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection
Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models
Innate antiviral immunity against dengue virus
Different STAT transcription complexes drive early and delayed responses to type I IFNs
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by th eiminosugar UV-4
Zika virus infects neural progenitors in the adult mouse brain and alters proliferation
Neuroterartogenic viruses and lessons for zika virus models
Mapping and role of the CD8+ T cell response during primary zika virus infection in mice
Novel strategies for discovering inhibitors of dengue and zika fever
Protective role of cross-reactive CD8 T cells against dengue virus infection
Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells
Modified mRNA vaccines protect against zika virus infection
ADE-ing and abetting Zika
Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists
Repurposing of the anti-malaria drug chloroquine for zika virus treatment and prophylaxis
Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent zika virus challenge
An IRF-3-, IRF-5-, and IRF-7-independent pathway of dengue viral resistance utilizes IRF-1 to stimulate type I and II interferon responses
T cell immunity to zika and dengue viral infections
Blocking zika virus vertical transmission
Development of zika virus vaccines
Immune response to dengue and zika
Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy
Deconvolution of pro- and antiviral genomic responses in Zika virus-infected and bystander macrophages
A longitudinal systems immunologic investigation of acute Zika virus infection in an individual infected while traveling to Caracas, Venezuela
Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice
Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection
Detection of zika virus in mouse mammary gland and breast milk
Genome-wide approaches to unravelling host-virus interactions in dengue and zika infections
CD4+ T cells promote humoral immunity and viral control during zika virus infection
Zika virus protease cleavage of host protein septin-2 mediates mitotic defects in neural progenitors
Antigenic cross-reactivity between zika and dengue viruses: is it time to develop a universal vaccine?
Cross-reactive T cell immunity to dengue and zika viruses: new insights Into vaccine development
SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model
Human polyclonal antibodies prevent lethal zika virus infection in mice
CD8+ T cells mediate protection against Zika virus induced by anNS3-based vaccine
Investigation of the Immunogenicity of Zika Glycan Loop
Targeting Endoplasmic Reticulum α-Glucosidase I With a Single-Dose Iminosugar Treatment Protects Against Lethal Influenza and Dengue Virus Infections
Protection against dengue virus requires a sustained balance of antibody and T cell responses
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
Whole genome sequencing of dengue virus serotype 2 from two clinical isolates and serological profile of dengue in the 2015-2016 Nepal outbreak.
Whole Genome Sequencing of Dengue Virus Serotype 2 from Two Clinical Isolates and AU3 AU2 Serological Profile of Dengue in the 2015–2016 Nepal Outbreak
Human FcRn expression and Type I Interferon signaling control Echovirus 11 pathogenesis in mice.
Repeated exposure to dengue virus elicits robust cross neutralizing antibodies against Zika virus in residents of Northeastern Thailand.
Emergence of a novel dengue virus 3 (DENV-3) genotype-I coincident with increased DENV-3 cases in Yangon, Myanmar between 2017 and 2019.
Animal models for SARS-Cov2/Covid19 research-A commentary.
The ability of Zika virus intravenous immunoglobulin to protect from or enhance Zika virus disease.
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
A zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity.
Acute-phase serum cytokine levels and correlation with clinical outcomes in children and adults with primary and secondary dengue virus infection in Myanmar between 2017 and 2019.
SREBP2-dependent lipid gene transcription enhances the infection of human dendritic cells by Zika virus.
Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
LJI scientists win ‘Prebys Research Heroes’ funding
Prebys Foundation celebrates ground-breaking female researchers
Common cold or COVID-19? Some T cells are ready to combat both
New LJI research demonstrates the importance of harnessing "cross-reactive" T cells to combat SARS-CoV-2
LJI-led team wins top Nucleate honors for virus vaccine development proposal
San Diego scientists work with business experts to advance dengue and Zika virus vaccine strategy
LJI Instructor Annie Elong Ngono, Ph.D., wins GVN support to advance infectious disease research
Elong Ngono, Ph.D., accepted to Global Virus Network Rising Star Mentorship Program
How human cells become Zika virus factories
LJI scientists uncover major clue toward developing a pan-flavivirus therapy
The life of a scientist studying Zika and dengue
Inside the work of immunologist Julia Timis
LJI and Charles River Laboratories to collaborate on COVID-19 research
New agreement paves the way for better mouse models to study how the human immune system fights SARS-CoV-2
Fernanda Ana-Sosa-Batiz wins AAI fellowship
"This fellowship opens up a lot of future opportunities.”
LJI and Synbal, Inc. partner to develop better COVID-19 models
New mouse models may shed light on the puzzling aspects of SARS-CoV-2 infection
Building true partnerships with overseas labs
As she advances global health, LJI Professor Sujan Shresta takes on three new research projects to support equity for scientists in South and Southeast Asia
Fighting Zika? Call in the T cells
Stopping emerging viruses could depend on getting T cells and antibodies to work together
Fighting mosquito-borne viruses requires a precise balance of immune cells
Future vaccines will need to harness the power of T cells in preventing Zika fever and Japanese encephalitis
